# To Explore the Efficacy and Safety of SHR-1701 Combined With Temozolomide in the Treatment of Advanced Melanoma

> **NCT05106023** · PHASE2 · UNKNOWN · sponsor: **Yong Chen** · enrollment: 31 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** SHR-1701
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT05106023
- **Lead sponsor:** Yong Chen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-21
- **Primary completion:** 2023-09-30
- **Final completion:** 2023-12-31
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2023-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05106023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05106023, "To Explore the Efficacy and Safety of SHR-1701 Combined With Temozolomide in the Treatment of Advanced Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05106023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*